Imago BioSciences to Participate in the 2022 Wedbush PacGrow Healthcare Conference
August 03 2022 - 4:57PM
Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage
biopharmaceutical company discovering and developing new medicines
for the treatment of myeloproliferative neoplasms (MPNs) and other
bone marrow diseases, today announced that Hugh Young Rienhoff,
Jr., MD, CEO of Imago BioSciences, will participate in an analyst
led Fireside Chat at the 2022 Wedbush PacGrow Healthcare Conference
on August 10, 2022, at 1:10 pm Eastern Time / 10:10 am Pacific
Time.
Interested parties can access the live webcast
of the Fireside Chat by visiting the Investor Relations section of
the company’s website at ir.imagobio.com. A webcast replay will be
available after the conclusion of the event for approximately 90
days.
Imago BioSciences
Imago BioSciences is a clinical-stage
biopharmaceutical company discovering and developing novel small
molecule product candidates that target lysine-specific demethylase
1 (LSD1), an enzyme that plays a central role in the production of
blood cells in the bone marrow. Imago is focused on improving the
quality and length of life for patients with cancer and bone marrow
diseases. Bomedemstat, an orally available, small molecule
inhibitor of LSD1, is the lead product candidate discovered by
Imago for the treatment of certain myeloproliferative neoplasms
(MPNs), a family of related, chronic cancers of the bone marrow.
Imago is evaluating Bomedemstat as a potentially disease-modifying
therapy in two Phase 2 clinical trials for the treatment of
essential thrombocythemia (NCT04254978) and myelofibrosis
(NCT03136185). Bomedemstat has U.S. FDA Orphan Drug and Fast Track
Designation for the treatment of ET and MF, European Medicines
Agency (EMA) Orphan Designation for the treatment of ET and MF, and
PRIority MEdicines (PRIME) Designation by the EMA for the treatment
of MF. The company is based in South San Francisco, California. To
learn more, visit www.imagobio.com,
www.myelofibrosisclinicalstudy.com,
www.etclinicalstudy.com and follow us on Twitter
@ImagoBioRx, Facebook and LinkedIn.
INVESTORSLaurence WattsGilmartin Group,
LLC.laurence@gilmartinir.com
MEDIAWill ZasadnyCanale
Communicationswill.zasadny@canalecomm.com
Source: Imago BioSciences
Imago BioSciences (NASDAQ:IMGO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Imago BioSciences (NASDAQ:IMGO)
Historical Stock Chart
From Sep 2023 to Sep 2024